Loading...

To contact Genta Investor Relations, please send your inquiries via email to info@genta.com

Genta Incorporated To Present At The BIO 2002 International Convention

June 7, 2002
Loading...

Berkeley Heights, NJ, June 7, 2002 -Genta Incorporated (Nasdaq: GNTA) announced today that the company has been invited to make several presentations at the BIO 2002 16th Annual International Biotechnology Convention & Exhibition in Toronto.

The first presentation will be made by Dr. Raymond P. Warrell, Jr., Genta's Chairman and CEO, and will occur on Tuesday, June 11, 2002 at 4:30 pm EST.  A live audio webcast will be available during the presentation and can be accessed via the following link: http://events01.activate.net/thomson/bio/2988/registration/default.asp .

Listeners should go to the site at least 15 minutes prior to the event to register. To save time on the day of the presentation, pre-registration is available now.  Replays will be available two hours after completion of the presentation and archived for 30 days.

In addition to Dr. Warrell's Corporate presentation, Thomas G. Burger, Vice President of Corporate Development, will present a talk entitled "The Little Fish Swims Downstream: The Trend in Early-Stage Partnering Deals Toward Greater Late-Stage Participation." Mr. Burger's presentation will occur on Wednesday, June 12, 2002, at 4:00 pm EST

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy.  The Company's research platform is anchored by DNA Medicines, particularly applications of antisense and decoy aptamers.  GenasenseTM, the Company"s lead compound, is currently in Phase 3 trials for melanoma, multiple myeloma, chronic lymphocytic leukemia, and non-small cell lung cancer.  The drug is also being studied in Phase 2 trials for leukemia, lymphoma, and prostate and small cell lung cancers.  Genta's drug pipeline also comprises a portfolio of small molecules, including Gallium Products for treatment of cancer and accelerated bone loss, and Androgenics Compounds for treatment of prostate cancer.  Genta aims to become a direct marketer of its pharmaceutical products in North America.  For more information about Genta, please visit our website at: http://www.genta.com/ .


Loading...

Loading...
Loading...
Genta Investor Kit
Create your own Genta Investor Kit.

Read More

Loading...
Loading...
Loading...